<DOC>
	<DOCNO>NCT02282358</DOCNO>
	<brief_summary>The purpose study learn study drug mocetinostat slow progression cancer people mutation CREBBP EP300 genetic makeup cancer . The potential side effect mocetinostat also study .</brief_summary>
	<brief_title>Study Mocetinostat Selected Patients With Mutations Acetyltransferase Genes Relapsed Refractory Diffuse Large B-Cell Lymphoma Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Patient provide sign study Informed Consent Form prior performance study relate procedurePatient ≥ 18 year age Patient histologically confirm diagnosis diffuse large B cell lymphoma follicular lymphoma harbor mutation CREBBP EP300 relapse refractory disease Patients diffuse large B cell lymphoma must receive least two prior therapy receive , decline ineligible autologous allogeneic stem cell transplant . Patients follicular lymphoma must receive least two prior therapy . Patients either diffuse large B cell lymphoma follicular lymphoma allow enroll receive 1 prior therapy felt candidate systemic chemotherapy . Patient least one measurable lesion ( ≥ 2 cm ) accord Cheson criterion [ 45 ] . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Patient adequate bone marrow organ function : Absolute neutrophil count ( ANC ) ≥ 1.0 x 10^9/L Platelets ≥ 75 x 10^9/L ( platelet transfusion within past 14 day ) Hemoglobin ( Hgb ) ≥ 9.0 g/dL ( RBC transfusion within past 14 day ) International Normalized Ratio ( INR ) ≤ 1.5 Serum Creatinine ≤ 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within 2.5 x ULN , ≤ 5.0 x ULN patient document hepatic involvement Serum bilirubin ≤ 1.5 x ULN ≤ 3.0 x ULN patient Gilbert Syndrome document hepatic involvement . Patients must fully recover major surgery acute toxic effect prior chemotherapy radiotherapy ( residual grade 1 toxicity , e.g . grade 1 peripheral neuropathy , residual alopecia allow ) Patient receive previous treatment HDAC inhibitor Patient evidence graft versus host disease ( GVHD ) Patient active history central nervous system ( CNS ) disease Patient impair cardiac function include follow : Presence history pericardial effusion ( definition provide and/or pericarditis . Acute myocardial infarction , symptomatic angina pectoris ≤ 6 month prior start study drug Presence congestive heart failure ≥ NYHA class 3 QTc &gt; 480 m screen ECG Screening LVEF &lt; 45 % echocardiography MUGA Uncontrolled cardiac arrhythmia include uncontrolled atrial fibrillation/atrial flutter/sinus tachycardia , complete leave bundle branch block , congenital long QT syndrome Presence permanent cardiac pacemaker Other clinically significant heart disease Subject take warfarin start treatment within 6 month prior start study treatment . Patient concurrent malignancy malignancy within 3 year study enrollment ( exception adequately treat basal squamous cell carcinoma nonmelanomatous skin cancer ) Patient concurrently use approve investigational antineoplastic agent Patient receive chemotherapy , targeted anticancer therapy , pelvic and/or paraaortic radiotherapy major surgery ≤ 4 week ( 6 week nitrosourea , monoclonal antibody mitomycinC ) prior start study drug recover side effect therapy Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption mocetinostat ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Patient currently receive increase chronic treatment ( &gt; 10 day ) corticosteroids another immunosuppressive agent . The following us corticosteroid permit : single dose , topical application ( e.g. , rash ) , inhale spray ( e.g. , obstructive airway disease ) , eye drop local injection ( e.g. , intraarticular ) . Patient history noncompliance medical regimen inability grant consent . Concomitant medication cause prolonged QT discontinue change different medication prior initiate study Patient currently treat drug know moderate strong inhibitor inducer isoenzyme CYP3A , treatment discontinue switched different medication prior start study drug . Patients must discontinue strong inducer least one week must discontinue strong inhibitor start treatment . Note : oral antidiabetic drug troglitazone pioglitazone CYP3A inducer . Patient known history HIV ( test mandatory ) , active Hepatitis B C infection . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive serum hCG laboratory test ( &gt; 5 mIU/mL ) Women child bear potential men reproductive potential , unwilling use adequate contraception study therapy 3 month thereafter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Mocetinostat</keyword>
	<keyword>14-106</keyword>
</DOC>